DURHAM, N.C. — The coronavirus attacks the body in so many ways, it has kept doctors guessing and sampling drugs they’ve used before for other purposes. Mike Sherman, the CEO of Chimerix, says it all started with a drug called DSTAT, under development to treat a serious and complicated type of cancer known as acute […]

Video: Stephen Smith, CEO of NOCD, talks about the increase of OCD therapy sessions since the outbreak of COVID-19 […]

Cyclacel Pharmaceuticals Inc., a Berkeley Heights-based biopharmaceutical company, has entered into an agreement with the University of Edinburgh to study its clinical stage CDK2/9 inhibitors, as potential early treatments for the inflammatory response observed in patients with COVID-19 disease. The partners will assess the suitability of Cyclacel’s medicines for use in safety and experimental studies. […]